$PLPL .40 on Alert! Plandaí Biotechnology, Inc
Post# of 144432
Plandaí Biotechnology is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 8500 acres, in the province of Mpumalanga, South Africa.
http://www.plandaibiotech.com/
Check out the chart! RSI is sitting at only 35 and the HOY is .82 ! >>> http://stockcharts.com/h-sc/ui?s=plpl
Investor Fact Sheet >>> http://plandaibiotech.com/plandai-biotech-investor2012.pdf
Products and benefits
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. We believe through our studies that this is between 60-80%, far exceeding anything currently available today.
Our extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011)